SCHEMBL4899889

SCHEMBL4899889

O=C(Nc1ccccc1)c1ccc(Nc2nc(Cl)nc3[nH]cnc23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.52
AURKB Q96GD4 2/20 0.52
INCENP Q9NQS7 1/20 0.52
AURKA O14965 3/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 1/20 0.46
KCNQ3 O43525 3/20 0.45
KCNQ2 O43526 3/20 0.45
KDR P35968 2/20 0.45
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
RAB9A P51151 1/20 0.44
PTPN1 P18031 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CCNA2 P20248 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7110570 0.86 POLB (0.55) EGFRAURKAPOLBKDRNPC1
SCHEMBL3001378 0.85 NFKB1 (0.46) EGFRMEN1KMT2A
SCHEMBL4894848 0.82 MKNK1 (0.52) EGFRAURKBAURKAPOLBKDR
SCHEMBL5841115 0.80 POLB (0.48) POLBNPC1RAB9A
SCHEMBL7108109 0.79 TOP2A (0.55) EGFRAURKAMEN1KMT2AKDM4E
SCHEMBL2996501 0.78 AURKA (0.46) EGFRAURKBAURKAMEN1KMT2A
SCHEMBL4846337 0.77 TTBK1 (0.43) MEN1KMT2A
SCHEMBL4890532 0.77 PDGFRA (0.49) EGFRAURKBINCENPAURKACDK2
SCHEMBL4890517 0.77 PDGFRA (0.49) EGFRAURKBINCENPAURKACDK2
SCHEMBL1590959 0.76 GRM5 (0.49) EGFRMEN1KMT2ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090849-A1 NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES AVENTIS PHARMA S.A. (FR) 2008-04-17 US disclosed
US-7041824-B2 Purine derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2006-05-09 US disclosed
US-20060074095-A1 Novel purine derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2006-04-06 US disclosed
US-20040063732-A1 Novel purine derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2004-04-01 US disclosed
EP-1347975-A1 NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES Aventis Pharma S.A. (FR) 2003-10-01 EP disclosed
WO-2002051843-A1 NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES AVENTIS PHARMA S.A. (FR) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063732-A1 Novel purine derivatives, preparation method and use as medicines CDK1, CDK6, PNP EGFR 4362/4885AURKB 229/4885INCENP 3458/4885
US-20080090849-A1 NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES CDK1, CDK6, PNP EGFR 4061/4885AURKB 166/4885INCENP 3305/4885
US-20060074095-A1 Novel purine derivatives, preparation method and use as medicines CDK1, CDK6, PNP EGFR 4239/4885AURKB 195/4885INCENP 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.